Pekka Kallunki

3.9k total citations · 1 hit paper
29 papers, 2.4k citations indexed

About

Pekka Kallunki is a scholar working on Molecular Biology, Neurology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Pekka Kallunki has authored 29 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 8 papers in Neurology and 7 papers in Cellular and Molecular Neuroscience. Recurrent topics in Pekka Kallunki's work include Parkinson's Disease Mechanisms and Treatments (8 papers), Cell Adhesion Molecules Research (7 papers) and RNA Research and Splicing (5 papers). Pekka Kallunki is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (8 papers), Cell Adhesion Molecules Research (7 papers) and RNA Research and Splicing (5 papers). Pekka Kallunki collaborates with scholars based in Denmark, United States and Finland. Pekka Kallunki's co-authors include Karl Tryggvason, Gerald M. Edelman, Frederick S. Jones, Karina Fog, Ann‐Louise Bergström, Patrik Brundin, Gesine Paul, Tiago F. Outeiro, Laura Pieri and Ronald Melki and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Angewandte Chemie International Edition.

In The Last Decade

Pekka Kallunki

29 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells

2011 670 citations Christian Hansen, Élodie Angot et al. Journal of Clinical Investigation profile →

Peers

Countries citing papers authored by Pekka Kallunki

Since Specialization

Citations

This map shows the geographic impact of Pekka Kallunki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pekka Kallunki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pekka Kallunki more than expected).

Fields of papers citing papers by Pekka Kallunki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pekka Kallunki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pekka Kallunki. The network helps show where Pekka Kallunki may publish in the future.

Co-authorship network of co-authors of Pekka Kallunki

This figure shows the co-authorship network connecting the top 25 collaborators of Pekka Kallunki. A scholar is included among the top collaborators of Pekka Kallunki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pekka Kallunki. Pekka Kallunki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The Amplification of Alpha‐Synuclein Amyloid Fibrils is Suppressed under Fully Quiescent Conditions 2024 ·Angewandte Chemie International Edition ·Azad Farzadfard, Thomas O. Mason, Antonín Kunka, Hossein Mohammad‐Beigi, (unknown), Jonas Folke, Susana Aznar, Pekka Kallunki, Alexander K. Buell	3
2	Randomized Phase I Trial of the α‐Synuclein Antibody Lu AF82422 2024 ·Movement Disorders ·(unknown), Jonas Wiedemann, Frank Larsen, (unknown), Pekka Kallunki, Dorte Kornerup Ditlevsen, (unknown), Didier Meulien	18
3	New prospects for 89Zr-immuno-PET in brain applications – Alpha-synucleinopathies 2024 ·Nuclear Medicine and Biology ·(unknown), Pedro Pereira, Albert D. Windhorst, (unknown), Florence Sotty, Pekka Kallunki, Allan Jensen, Benny Bang‐Andersen, Guus A.M.S. van Dongen, Wissam Beaino, Daniëlle J. Vugts	2
4	A mouse model of the schizophrenia-associated 1q21.1 microdeletion syndrome exhibits altered mesolimbic dopamine transmission 2017 ·Translational Psychiatry ·Jacob Nielsen, Kim Fejgin, Florence Sotty, Vibeke Nielsen, Arne Mørk, Claus T. Christoffersen, Leonid Yavich, (unknown), (unknown), Peter H. Larsen, Jan Egebjerg, Thomas Werge, Pekka Kallunki, Kenneth Vielsted Christensen, Michael Didriksen	34
5	Persistent gating deficit and increased sensitivity to NMDA receptor antagonism after puberty in a new mouse model of the human 22q11.2 microdeletion syndrome: a study in male mice 2016 ·Journal of Psychiatry and Neuroscience ·Michael Didriksen, Kim Fejgin, Simon Nilsson, Michelle Rosgaard Birknow, Hannah M. Grayton, Peter H. Larsen, (unknown), Vibeke Nielsen, Pau Celada, Noemí Santana, Pekka Kallunki, Kenneth Vielsted Christensen, Thomas Werge, Tine B. Stensbøl, Jan Egebjerg, François Gastambide, Francesc Artigas, Jesper F. Bastlund, Jacob Nielsen	57
6	Antibodies against the C-terminus of α-synuclein modulate its fibrillation 2016 ·Biophysical Chemistry ·Cagla Sahin, Nikolai Lorenzen, (unknown), Gunna Christiansen, Ian Max Møller, (unknown), Lars Østergaard Pedersen, Karina Fog, Pekka Kallunki, Daniel E. Otzen	23
7	Development of P assive I mmunotherapies for S ynucleinopathies 2015 ·Movement Disorders ·Ann‐Louise Bergström, Pekka Kallunki, Karina Fog	59
8	Evaluation of 309 molecules as inducers of CYP3A4, CYP2B6, CYP1A2, OATP1B1, OCT1, MDR1, MRP2, MRP3 and BCRP in cryopreserved human hepatocytes in sandwich culture 2014 ·Xenobiotica ·Lassina Badolo, (unknown), (unknown), Ulf Norinder, Pekka Kallunki, Dino Montanari	31
9	Rasagiline Ameliorates Olfactory Deficits in an Alpha-Synuclein Mouse Model of Parkinson's Disease 2013 ·PLoS ONE ·Géraldine Petit, (unknown), (unknown), Pekka Kallunki, Karina Fog, Cheryl Fitzer‐Attas, Patrik Brundin	35
10	Effects of exogenous alpha-synuclein on stimulated dopamine overflow in dorsal striatum 2013 ·Neuroscience Letters ·Anssi Pelkonen, Pekka Kallunki, Leonid Yavich	3
11	A Mouse Model that Recapitulates Cardinal Features of the 15q13.3 Microdeletion Syndrome Including Schizophrenia- and Epilepsy-Related Alterations 2013 ·Biological Psychiatry ·Kim Fejgin, Jacob Nielsen, Michelle Rosgaard Birknow, Jesper F. Bastlund, Vibeke Nielsen, (unknown), Hreinn Stefánsson, Stacy Steinberg, Helge B. D. Sørensen, (unknown), Peter H. Larsen, Ib Vestergaard Klewe, (unknown), Kāri Stefánsson, Thomas Werge, Pekka Kallunki, Kenneth Vielsted Christensen, Michael Didriksen	81
12	α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells breakdown → 2011 ·Journal of Clinical Investigation ·Christian Hansen, Élodie Angot, Ann‐Louise Bergström, Jennifer A. Steiner, Laura Pieri, Gesine Paul, Tiago F. Outeiro, Ronald Melki, Pekka Kallunki, Karina Fog, Jiayi Li, Patrik Brundin	670
13	Hippocampal CA1 region shows differential regulation of gene expression in mice displaying extremes in behavioral sensitization to amphetamine: relevance for psychosis susceptibility? 2011 ·Psychopharmacology ·Nicole A. Datson, (unknown), Inge E.M. de Jong, Peter J. Steenbergen, Kenneth Vielsted Christensen, Krzysztof Potempa, Jan T. Pedersen, Jan Egebjerg, Pekka Kallunki, Erik B. Nielsen, E. R. de Kloet, Michael Didriksen	7
14	Levetiracetam attenuates hippocampal expression of synaptic plasticity-related immediate early and late response genes in amygdala-kindled rats 2010 ·BMC Neuroscience ·Kenneth Vielsted Christensen, Henrik Leffers, William P. Watson, Connie Sánchez, Pekka Kallunki, Jan Egebjerg	44
15	Three-cohort targeted gene screening reveals a non-synonymous TRKA polymorphism associated with schizophrenia 2009 ·Journal of Psychiatric Research ·(unknown), Karen M. J. van Loo, (unknown), Srdjan Djurovic, Ole A. Andreassen, Thomas Folkmann Hansen, Thomas Werge, Pekka Kallunki, Jan T. Pedersen, Gerard J.M. Martens	25
16	The neural restrictive silencer element can act as both a repressor and enhancer of L1 cell adhesion molecule gene expression during postnatal development 1998 ·Proceedings of the National Academy of Sciences ·Pekka Kallunki, Gerald M. Edelman, Frederick S. Jones	62
17	Structure of the Human Laminin γ2 Chain Gene (LAMC2): Alternative Splicing with Different Tissue Distribution of Two Transcripts 1996 ·Genomics ·Tomi T. Airenne, (unknown), Kirsi Sainio, Tuula Kallunki, Pekka Kallunki, Hannu Sariola, Karl Tryggvason	40
18	Silencer Elements Modulate the Expression of the Gene for the Neuron-Glia Cell Adhesion Molecule, Ng-CAM 1995 ·Journal of Biological Chemistry ·Pekka Kallunki, Stephen Jenkinson, Gerald M. Edelman, Frederick S. Jones	76
19	Human basement membrane heparan sulfate proteoglycan core protein: a 467-kD protein containing multiple domains resembling elements of the low density lipoprotein receptor, laminin, neural cell adhesion molecules, and epidermal growth factor. 1992 ·The Journal of Cell Biology ·Pekka Kallunki, Karl Tryggvason	190
20	Cloning of human heparan sulfate proteoglycan core protein, assignment of the gene (HSPG2) to 1p36.1→p35 and identification of a BamHI restriction fragment length polymorphism 1991 ·Genomics ·Pekka Kallunki, Roger L. Eddy, M.G. Byers, Marjo Kestilä, Thomas B. Shows, Karl Tryggvason	40

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact